|[August 21, 2013]
Research and Markets: Top 10 Pharmaceutical Companies in India Benchmark Report - Niche Drug Revolution: Has India's Generics Boom Peaked?
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/qx776j/pharmaleaders)
has announced the addition of the "PharmaLeaders:
Top 10 Pharmaceutical Companies in India Benchmark Report - Competitive
Analysis of the Leading Players in 2013" report to their
Niche Drug Revolution (News - Alert): Has India's Generics Boom Peaked?
Many Indian pharmaceutical companies will increasingly look to the
development of drugs within niche therapy areas and move away from the
overcrowded and increasingly challenging generics landscape, says
research and consulting firm The authors.
According to the company's latest report*, major pharmaceutical
manufacturers in India will spend more on R&D in the near future as they
target potentially lucrative and relatively underdeveloped niche therapy
area drugs markets.
Companies such as Ranbaxy, Dr. Reddy's, Lupin and Wockhardt have already
been making moves towards niche drug production, with R&D investments
increasing in recen times, says Adefemi Adenuga, analyst with The
authors's Healthcare Industry Dynamics Team.
Many Indian companies already possess considerable manufacturing
capabilities and would be able to leverage their experience and
infrastructure into achieving scale economies in the development and
production of niche drugs.
The generics sector - which currently dominates India's pharmaceuticals
market - does not guarantee long-term profitability or sustainable
financial growth, and there are fewer barriers to market entry than
there are for branded therapeutics, which require significantly greater
resources. Accordingly, competition in the generics sector is fierce and
profit margins are slim.
Big Pharma's rising interest in emerging markets is expected to further
squeeze the profitability of India's generics manufacturers,
particularly that of smaller firms. Major players from Europe, Asia, and
North America are investing significantly in India and taking advantage
of the nation's relatively cheap resources.
While this interest will inevitably put pressure on India's domestic
firms, it will also play a key role in driving the country's
pharmaceutical market value, with The authors forecasting revenue to
increase from an estimated $17 billion in 2012 to $54 billion in 2020.
Key Topics Covered:
1 Tables & Figures
3 India's Pharmaceutical Industry Dynamics
4 Company Analysis
5 Benchmark Rankings
6 Financial Management
7 Expense Management
8 Capital Management
9 Resource Management
10 Geographical Segmentation
11 Strategic Outlook
For more information visit http://www.researchandmarkets.com/research/qx776j/pharmaleaders
[ Back To Technology News's Homepage ]